Leo Pharma has started phase IIb study with antibody treatment
The purpose of the study was to assess the efficacy and safety of different doses of the treatment in adults with moderate to severe atopic eczema.
Leo Pharma has initiated a phase IIb study with the antibody treatment Leo 138559 for moderate to severe atopic eczema (AD). The pharmaceutical company announces this in a press release that also states that the treatment will be known as temtokibart in the future.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
